Drug intelligence / Profile preview

Fuzheng Xiaoji pill

Development stage: Preclinical
Lead developer: Guang'anmen Hospital
Administration: Oral

Overview

Fuzheng Xiaoji pill (also known as Fuzheng Xiaoji Wan) is a traditional Chinese medicine (TCM) herbal formulation developed by Guang'anmen Hospital, China Academy of Chinese Medical Sciences. It is designed based on the TCM therapeutic principle of 'strengthening the body's healthy qi and eliminating accumulation' (Fuzheng Xiaoji). The formulation is primarily being evaluated as a supportive or complementary therapy for the treatment of metastatic pancreatic cancer, particularly in combination with best supportive care, and has been studied in clinical trials in China comparing its efficacy and safety against standard chemotherapy regimens like FOLFIRINOX.

Other names: Fuzheng Xiaoji WanFu-Zheng-Xiao-Ji pill扶正消积丸

Beyond the preview

Go deeper on Fuzheng Xiaoji pill.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuzheng Xiaoji pill.

Explore the full profile